NCT03637634 (CANPCSS) is a clinical trial in NPC Patients, sponsored by Hai-Qiang Mai,MD,PhD.

Who is sponsoring NCT03637634?

NCT03637634 is sponsored by Hai-Qiang Mai,MD,PhD.

What condition does NCT03637634 study?

NCT03637634 studies NPC Patients.

Is NCT03637634 still recruiting?

NCT03637634 is currently not yet recruiting. Last updated 28 August 2018.

Last reviewed 2018-08-28 · How we verify

NCT03637634: CANPCSS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Children and Adolescents Nasopharyngeal Carcinoma Survivor Study

Not yet recruiting Last updated 28 August 2018

What this trial tests

trial in NPC Patients in 1,000 participants. Not yet recruiting.

Timeline

1 September 2018

Primary endpoint
31 December 2030

31 December 2035

Quick facts

Lead sponsor	Hai-Qiang Mai,MD,PhD
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	1 September 2018
Primary completion	31 December 2030
Estimated completion	31 December 2035

Conditions studied

NPC Patients — all drugs for NPC Patients →

Sponsor

Hai-Qiang Mai,MD,PhD

Who can join

Under 21, any sex, with NPC Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Children and Adolescents Nasopharyngeal Carcinoma Survivor Study will investigate the long-term effects of nasopharyngeal carcinoma (NPC) and its associated therapies. A prospective and retrospective cohort study will be conducted through a multi-institutional collaboration. This project will study children and adolescents exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or surgery, who are at increased risk of late-occurring adverse health outcomes. A group of sibling controls will be identified and data collected for comparison purposes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for NPC Patients

Currently open trials in the same condition.

NCT07232680 — Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon Chemoradiotherapy · recruiting

Other Hai-Qiang Mai,MD,PhD trials

Trials by the same sponsor.

NCT07072000 — Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity · Phase 3 · not yet recruiting
NCT06912698 — Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03637634 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hai-Qiang Mai,MD,PhD
Last refreshed: 28 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03637634.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing